 OncoSec Medical Incorporated OncoSec Nasdaq: ONCS, a company developing late-stage intratumoral cancer immunotherapies, today announced data from a feasibility study of its visceral lesion applicator VLA electroporation device that were presented at the Annual Meeting of the Society of Interventional Oncology SIO in New Orleans. The study, which was awarded Best Technology Scientific Abstract at SIO, showed investigators were able to successfully and safely reach target organs located deep inside the body and deploy the devices applicator tip in a large animal model. 